Discussion: Given that the ALK inhibitors are the treatment of choice for advanced lung cancer patients with ALK rearrangement. Our report demonstrated the potential feasibility of alectinib re-use in cases of severe druginduced ILD. READ ARTICLE
Journal of Oncology Pharmacy Practice DOI:10.1177/1078155220961557
Authors: Huang JR, Chou CW, Chao HS.
